Skip to content
Review Open access

Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease

Aug 2026 · International Journal of Developmental Neuroscience · Vol 86 · 0 citations · 20 references
Medicine

TL;DR

The dual and stage‐dependent roles of microglia and astrocytes are explored, discussion of blood–brain barrier dysfunction and peripheral immune infiltration as underappreciated pathogenic contributors are expanded, and emerging evidence linking neuroinflammation specifically to tau pathology is integrated.

Abstract

Alzheimer's disease (AD) represents the most prevalent neurodegenerative disorder worldwide, affecting millions of individuals and imposing substantial socioeconomic burdens. While traditional research has focused on amyloid‐β (Aβ) plaques and neurofibrillary tangles as primary pathological hallmarks, mounting evidence implicates neuroinflammation as a critical third pillar in AD pathogenesis. This review critically evaluates current understanding of neuroinflammatory mechanisms in AD, examining the complex interplay between cellular mediators, molecular pathways and environmental triggers across a temporal disease‐stage framework. We explore the dual and stage‐dependent roles of microglia and astrocytes, expand discussion of blood–brain barrier (BBB) dysfunction and peripheral immune infiltration as underappreciated pathogenic contributors, and integrate emerging evidence linking neuroinflammation specifically to tau pathology and its stereotyped propagation through the brain. Diagnostic biomarkers, including translocator protein–positron emission tomography (TSPO‐PET) and plasma glial fibrillary acidic protein (GFAP), are evaluated with explicit attention to clinical utility, technical limitations, and their relationship to established AD biomarkers. Therapeutic strategies are critically assessed with careful distinction between preclinical proof‐of‐concept data and available clinical evidence, and key translational challenges are highlighted throughout. The review emphasizes the need for stage‐appropriate intervention windows, patient stratification by neuroinflammatory endotype, and biologically rational combination strategies. Understanding neuroinflammation's temporal and spatial dynamics offers promising but as yet insufficiently realized avenues for early intervention and disease modification in AD.

Read PDF

Similar papers

Review Open access Aug 2026

Microglia-mediated neuroinflammation in Alzheimer’s disease: mechanisms and emerging therapeutic targets

A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematically discussed.

Lian-Jing Xu, Ying Zhang, Li Jiang et al. · 0 citations
Review Aug 2026

Neuroinflammatory and molecular pathways in Alzheimer’s disease: mechanistic crosstalk and emerging therapeutic opportunities

Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.

Abhay Thakur, Rohit Sharma, Sneha Kumari et al. · 0 citations
Review Open access Jul 2026

Neuroinflammation in Alzheimer’s disease-associated sensory dysfunction: mechanistic links, actionable targets and therapeutic strategies

This work aimed to identify AD-related olfactory and visual or retinal abnormalities, combine core inflammatory pathways and their interactions with amyloid-β and tau pathology, and summarize actionable targets and candidate interventions along a “receptor–intracellular signaling-inflammasome-effector” axis, to inform earlier-stage detection and mechanism-guided intervention in AD.

Yanjiao Xu, Guimei Zhang, Xinran Cui et al. · 0 citations
Review Open access Jul 2026

Neuroinflammatory mechanisms and immunomodulatory therapies in Alzheimer's disease

This review synthesises current understanding of neuroinflammatory pathogenesis in AD, with emphasis on Microglial polarisation (M1/M2), Disease-Associated Microglia (DAM), TREM2 signalling, and reactive astrocyte conversion.

Zizhen Ren · 0 citations
Review Jul 2026

Neuroinflammation in neurodegenerative diseases: pathogenic pathways and emerging pharmacotherapeutic targets in Alzheimer’s and Parkinson’s disease

New knowledge about the protective and detrimental aspects of neuroinflammation in AD and PD is summarized, providing an analysis on these developing prospects for targeted interventions toward slowing or stopping neurodegeneration.

R. Kumar, Kamaljeet, Sourabh Kosey · 0 citations
Review Open access Jul 2026

Neuroinflammation in Alzheimer’s and Parkinson’s diseases: pathogenic mechanisms and therapeutic strategies

It is illustrated how endogenous pathological triggers, such as amyloid-β (Aβ) peptide, hyperphosphorylated tau, and α-synuclein, activate glial cells, contributing to chronic neuroinflammation that exacerbates neurodegeneration.

Qinqin Wang, Qing-qing Sun, Yong-shun Guo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.